Baseline Characteristics of Study Cohort
| Characteristic (n = 81) | Total or median |
| Age (y) | 61 (15) |
| Time between diagnosis and radioembolization (y) | 6.0 (7.3) |
| Prior local treatment | 20 (25%) |
| Surgery | 8 (10%) |
| RFA | 9 (11%) |
| TACE | 4 (5%) |
| LITT | 1 (1%) |
| Multiple | 2 (2%) |
| UICC stage at initial diagnosis | |
| 1 | 4 (5%) |
| 2a | 29 (36%) |
| 2b | 13 (16%) |
| 3a | 11 (14%) |
| 3b | 8 (10%) |
| 4 | 16 (20%) |
| Tumor expression profile | |
| PR+ | 40 (49%) |
| ER+ | 60 (74%) |
| Her2/neu+ | 28 (35%) |
| CA15-3 (U/mL) | 137 (395) |
| Carcinoembryonic antigen (ng/mL) | 12 (28) |
| Tumor-to-liver ratio | |
| <25% | 49 (60%) |
| 25%–50% | 24 (30%) |
| ≥50% | 8 (10%) |
| Radioactivity delivered (GBq) | 1.6 (0.6) |
RFA = radiofrequency ablation; TACE = transcatheter arterial chemoembolization; LITT = laser-induced thermotherapy; UICC = International Union Against Cancer; PR+ = progesterone receptor status positive; ER+ = estrogen receptor status positive; Her-2/neu+ = Her-2/neu status positive.
Given are total numbers (with percentages in parentheses) or median (with IQRs in parentheses).